TABLE 1.
Demographic and baseline patient characteristics
| Characteristics |
N° of patients (N = 26) |
% |
|---|---|---|
| Gender | ||
| Male/Female | 10/16 | 38.5/61.5 |
| Age, median (range)/y | 63 (27‐74) | |
| Performance status (ECOG) | ||
| 0/1 | 10/16 | 38.5/61.5 |
| Masaoka‐Koga stages | ||
| IVa/IVb/Recurrence | 4/14/8 | 15.4/53.8/30.8 |
| Smoking history | ||
| Never/previous or current | 9/17 | 34.6/65.4 |
| Metastatic sites (overlapped) | ||
| Lung | 5 | |
| Liver | 6 | |
| Lymph nodes | 4 | |
| Pleura | 5 | |
| Pericardial | 1 | |
| Bone | 7 | |
| Brain | 2 | |
| Histological subtype (institutional diagnosis) | ||
| Squamous cell carcinoma/Borderline/Unknown | 23/1/2 | 88.5/3.8/7.7 |
| Previous chemotherapy | ||
| ADOC | 1 | 3.8 |
| Cisplatin‐irinotecan | 3 | 11.5 |
| Cisplatin‐etoposide | 2 | 7.7 |
| Carboplatin‐paclitaxel | 20 | 77.0 |
| Previous history of radiotherapy | ||
| Yes/No | 10/16 | 38.5/61.5 |
Abbreviations: ADOC, adriamycin, cisplatin, vincristine, and cyclophosphamide; ECOG PS, Eastern Cooperative Oncology Group Performance Status; No, number.